Today to seek your help in spreading the word about one of the many ongoing efforts Mount Sinai is working on towards advancing care for COVID-19 – in this particular case, identifying volunteers who may be right for the COVID-19 study below.
COVID-19 Hyperimmune Globulin Study Details
Emergent BioSolutions and the Icahn School of Medicine at Mount Sinai are conducting a Phase 1, double-blinded, placebo-controlled study of COVID-19 hyperimmune immunoglobulin in healthy volunteers who have never been infected with COVID-19.
What is COVID-19 Hyperimmune Immunoglobulin?
COVID-19 hyperimmune immunoglobulin contains purified antibodies against SARS-CoV-2, the virus that causes COVID-19.
It is made from the convalescent plasma of individuals recently infected with COVID-19.
This COVID-19 hyperimmune immunoglobulin has the potential to protect and treat against COVID-19 and this study is the first step in evaluating the effectiveness of this therapy.
Mount Sinai’s COVID Clinical Trials Unit is looking for healthy individuals (ages 18-60) who have never tested positive for COVID-19 nor have received any COVID-19 vaccines.
One overnight stay is required. Compensation for time and travel will be provided.
How to get involved
Please direct volunteers to call 212-824-7714 or email email@example.com to see if they qualify.